Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

April 2026

Ayahuasca

What April 2026's 7 new studies found, synthesized from the papers below. All Ayahuasca research →

The synthesis

Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Ayahuasca, yage, hoasca, banisteriopsis, then ranked by relevance.

Research on ayahuasca published in April 2026 indicates that it shows promise as a rapid-acting intervention for reducing suicidal ideation and depressive symptoms, with consistent evidence from systematic reviews and a large longitudinal study showing improvements in personality, quality of life, and decentering. However, the evidence is limited by small sample sizes, methodological heterogeneity, and a lack of large-scale, rigorous longitudinal studies.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Ayahuasca Therapy: Possible Reduction of Suicidal Ideation in Treatment-Resistant Depression - A Systematic Review. 2026
Supports

Ayahuasca administration is consistently associated with rapid and significant reductions in suicidal ideation and depressive symptoms in patients with depressive disorders.

systematic review Sample size: 5

Symmetrical Global Mental Health (Sym-GMH): Ayahuasca and shipibo traditional medicine for lasting changes in personality and quality of life 2026
Supports

Significant reductions in Neuroticism and Openness, increases in Extraversion, improved quality of life across all domains, and increased decentering capacities with moderate to high effect sizes; 91.7% reported long-term benefits.

prospective longitudinal study Sample size: 264

Single exposure to Ayahuasca reverses chronic stress effects on sociability, anxiety, cortisol, and BDNF in zebrafish 2026
Supports

A single exposure to ayahuasca restored chronic stress-induced impairments in sociability, anxiety-like behavior, and reversed changes in cortisol and BDNF levels.

preclinical animal study

POTENCIAL TERAPÊUTICO DA HOASCA NO TRATAMENTO DA DEPRESSÃO: REVISÃO DE ESCOPO 2026
Supports

Antidepressant effects of hoasca/ayahuasca are related to DMT and β-carboline interactions, increasing serotonin availability and BDNF production, with rapid and lasting clinical effects.

scoping review Sample size: 12

Responsible Ceremonial Medicine: A Review of Current Evidence, Safety Protocols, and Ethical Considerations for Professional Practice 2026
Supports

Reviews clinical evidence for ayahuasca in major depression and treatment-resistant depression, highlighting neuroplasticity mechanisms and safety protocols.

review

Points of agreement

  • Ayahuasca shows rapid and significant reductions in depressive symptoms and suicidal ideation.
  • Therapeutic effects are linked to neuroplasticity, BDNF upregulation, and modulation of brain networks.
  • Adverse effects are minimal in controlled settings.

Conflicts

  • The systematic review (article_id: 28190) notes methodological heterogeneity among studies, while the scoping review (article_id: 28223) does not address this directly.
  • The longitudinal study (article_id: 28353) found a decrease in Openness, which contrasts with some other psychedelic research that often reports increases.

Gaps

  • Lack of large-scale, randomized controlled trials with long-term follow-up.
  • Durability of effects beyond 12 months is not established.
  • Limited data on diverse populations and real-world clinical settings.
  • Optimal dosing and treatment protocols are not standardized.
Browse these studies in the library